HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?

Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organi...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2012
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23952
Acceso en línea:
https://repository.urosario.edu.co/handle/10336/23952
Palabra clave:
Nevirapine
Nonnucleoside reverse transcriptase inhibitor
Zidovudine
Blood toxicity
Brazil
Cd4 lymphocyte count
Central america
Follow up
Gene mutation
Gene sequence
Geographic distribution
Heterosexual male
Highly active antiretroviral therapy
Human
Human immunodeficiency virus 1 infection
Mexico
Prevalence
Rash
Review
Risk factor
Socioeconomics
South and central america
Venezuela
Virus transmission
World health organization
Caribbean region
Female
Guidelines as topic
Hiv infections
Hiv-1
Humans
Latin america
Male
Prevalence
Caribbean
Drug resistance
Genotype
Hiv-1
Latin america
Naive
viral
missense
Drug resistance
Mutation
Rights
License
Abierto (Texto Completo)
id EDOCUR2_71a6f7382741ba78b95fd46ba78faace
oai_identifier_str oai:repository.urosario.edu.co:10336/23952
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 3e55916f-82d6-4efb-8ace-19e4bab6bfe0-17ef2b174-79ad-4db9-aeaa-7493403d9977-1f1f5fc82-68b8-4245-85be-ccfaaaa08370-1e0288969-4908-446e-b7f8-e9388878fc5c-1175b76c7-4c59-4c59-99e3-de4b980e2095-1693c47de-32d7-4155-a17d-efe0ac1f9631-107a5da01-1828-47eb-befd-3d38811325e1-12020-05-26T00:07:00Z2020-05-26T00:07:00Z2012Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organization (WHO). Consequently, our aim was to review all relevant studies on transmitted drug resistance in Latin America and the Caribbean countries, to analyze its levels, to identify the frequency of transmitted drug resistance mutations, and to put these results in the context of the local Latin American and Caribbean countries settings. A systematic search of Spanish, Portuguese, and English literature was performed in databases and international conferences for the period June 1999 to May 2011. In addition, sequences were downloaded from the Los Alamos and Stanford databases and the transmitted drug resistance was reanalyzed according to the WHO Surveillance Drug Resistance Mutation list 2009. In total, 50 articles, 27 abstracts, and 1,922 patients were included. The resistance varied geographically, but most of the countries have reached the WHO threshold of 5% of resistance. According to the sequences available in public databases, the overall prevalence in Latin America and the Caribbean countries for the period 1996-2009 was 7.7% and by region it was 4.3% for the Caribbean, 3.9% for Mexico, 9.4% for Brazil, 10.5% for the Andean region and 4.9% for the Southern Cone. For the last four investigated years (2006-2009), the information was restricted to Brazilian and Venezuelan studies and revealed an overall transmitted drug resistance of 10%. Throughout the study period, limited information was available for the Caribbean and Central American countries. These findings support the need for developing comprehensive surveys of transmitted drug resistance in these regions.application/pdf11396121https://repository.urosario.edu.co/handle/10336/23952eng267No. 4256AIDS ReviewsVol. 14AIDS Reviews, ISSN:11396121, Vol.14, No.4 (2012); pp. 256-267https://app.dimensions.ai/details/publication/pub.1078664397Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURNevirapineNonnucleoside reverse transcriptase inhibitorZidovudineBlood toxicityBrazilCd4 lymphocyte countCentral americaFollow upGene mutationGene sequenceGeographic distributionHeterosexual maleHighly active antiretroviral therapyHumanHuman immunodeficiency virus 1 infectionMexicoPrevalenceRashReviewRisk factorSocioeconomicsSouth and central americaVenezuelaVirus transmissionWorld health organizationCaribbean regionFemaleGuidelines as topicHiv infectionsHiv-1HumansLatin americaMalePrevalenceCaribbeanDrug resistanceGenotypeHiv-1Latin americaNaiveviralmissenseDrug resistanceMutationHIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Pineda-Peña A.-C.Bello D.-C.Sussmann O.Vandamme A.-M.Vercauteren J.Van Laethem K.Gómez-López A.10336/23952oai:repository.urosario.edu.co:10336/239522022-05-02 07:37:14.710715https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
title HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
spellingShingle HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
Nevirapine
Nonnucleoside reverse transcriptase inhibitor
Zidovudine
Blood toxicity
Brazil
Cd4 lymphocyte count
Central america
Follow up
Gene mutation
Gene sequence
Geographic distribution
Heterosexual male
Highly active antiretroviral therapy
Human
Human immunodeficiency virus 1 infection
Mexico
Prevalence
Rash
Review
Risk factor
Socioeconomics
South and central america
Venezuela
Virus transmission
World health organization
Caribbean region
Female
Guidelines as topic
Hiv infections
Hiv-1
Humans
Latin america
Male
Prevalence
Caribbean
Drug resistance
Genotype
Hiv-1
Latin america
Naive
viral
missense
Drug resistance
Mutation
title_short HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
title_full HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
title_fullStr HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
title_full_unstemmed HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
title_sort HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
dc.subject.keyword.spa.fl_str_mv Nevirapine
Nonnucleoside reverse transcriptase inhibitor
Zidovudine
Blood toxicity
Brazil
Cd4 lymphocyte count
Central america
Follow up
Gene mutation
Gene sequence
Geographic distribution
Heterosexual male
Highly active antiretroviral therapy
Human
Human immunodeficiency virus 1 infection
Mexico
Prevalence
Rash
Review
Risk factor
Socioeconomics
South and central america
Venezuela
Virus transmission
World health organization
Caribbean region
Female
Guidelines as topic
Hiv infections
Hiv-1
Humans
Latin america
Male
Prevalence
Caribbean
Drug resistance
Genotype
Hiv-1
Latin america
Naive
topic Nevirapine
Nonnucleoside reverse transcriptase inhibitor
Zidovudine
Blood toxicity
Brazil
Cd4 lymphocyte count
Central america
Follow up
Gene mutation
Gene sequence
Geographic distribution
Heterosexual male
Highly active antiretroviral therapy
Human
Human immunodeficiency virus 1 infection
Mexico
Prevalence
Rash
Review
Risk factor
Socioeconomics
South and central america
Venezuela
Virus transmission
World health organization
Caribbean region
Female
Guidelines as topic
Hiv infections
Hiv-1
Humans
Latin america
Male
Prevalence
Caribbean
Drug resistance
Genotype
Hiv-1
Latin america
Naive
viral
missense
Drug resistance
Mutation
dc.subject.keyword.eng.fl_str_mv viral
missense
Drug resistance
Mutation
description Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organization (WHO). Consequently, our aim was to review all relevant studies on transmitted drug resistance in Latin America and the Caribbean countries, to analyze its levels, to identify the frequency of transmitted drug resistance mutations, and to put these results in the context of the local Latin American and Caribbean countries settings. A systematic search of Spanish, Portuguese, and English literature was performed in databases and international conferences for the period June 1999 to May 2011. In addition, sequences were downloaded from the Los Alamos and Stanford databases and the transmitted drug resistance was reanalyzed according to the WHO Surveillance Drug Resistance Mutation list 2009. In total, 50 articles, 27 abstracts, and 1,922 patients were included. The resistance varied geographically, but most of the countries have reached the WHO threshold of 5% of resistance. According to the sequences available in public databases, the overall prevalence in Latin America and the Caribbean countries for the period 1996-2009 was 7.7% and by region it was 4.3% for the Caribbean, 3.9% for Mexico, 9.4% for Brazil, 10.5% for the Andean region and 4.9% for the Southern Cone. For the last four investigated years (2006-2009), the information was restricted to Brazilian and Venezuelan studies and revealed an overall transmitted drug resistance of 10%. Throughout the study period, limited information was available for the Caribbean and Central American countries. These findings support the need for developing comprehensive surveys of transmitted drug resistance in these regions.
publishDate 2012
dc.date.created.spa.fl_str_mv 2012
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:07:00Z
dc.date.available.none.fl_str_mv 2020-05-26T00:07:00Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.issn.none.fl_str_mv 11396121
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/23952
identifier_str_mv 11396121
url https://repository.urosario.edu.co/handle/10336/23952
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 267
dc.relation.citationIssue.none.fl_str_mv No. 4
dc.relation.citationStartPage.none.fl_str_mv 256
dc.relation.citationTitle.none.fl_str_mv AIDS Reviews
dc.relation.citationVolume.none.fl_str_mv Vol. 14
dc.relation.ispartof.spa.fl_str_mv AIDS Reviews, ISSN:11396121, Vol.14, No.4 (2012); pp. 256-267
dc.relation.uri.spa.fl_str_mv https://app.dimensions.ai/details/publication/pub.1078664397
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167640749375488